2018 年第 8 期 第 13 卷

西帕依麦孜彼子胶囊联合盐酸坦洛新缓释片治疗ⅢA型慢性非细菌性前列腺炎的临床效果

Clinical effect of Xipayimaibizi capsules combined with tamsulosin hydrochloride sustained-release tablets on type ⅢA chronic nonbacterial prostatitis

作者：霍振清迟强

英文作者：

单位：572000海南省三亚市，海南省第三人民医院泌尿外科（霍振清）；067020承德医学院附属医院泌尿外科（迟强）

英文单位：

关键词：慢性非细菌性前列腺炎；西帕依麦孜彼子胶囊；盐酸坦洛新缓释片

英文关键词：

• 摘要：

• 【摘要】目的    探讨中成药西帕依麦孜彼子胶囊联合盐酸坦洛新缓释片治疗ⅢA型慢性非细菌性前列腺炎的临床效果。方法    选取2010年9月至2013年9月在承德医学院附属医院就诊的130例ⅢA型慢性非细菌性前列腺炎患者，采用随机数字表法分为观察组和对照组，各65例。在一般治疗的基础上，观察组口服西帕依麦孜彼子胶囊0.5 g/次、3次/d和盐酸坦洛新缓释片0.2 mg/次、1次/d；对照组口服盐酸坦洛新缓释片0.2 mg/次，1次/d；2组均治疗5周。采用美国国立卫生研究院慢性前列腺炎症状评分量表（NIH-CPSI）评估临床疗效。观察治疗过程中的不良反应发生情况。结果    治疗后观察组疼痛或不适评分、排尿症状评分、生活质量评分及NIH-CPSI总评分均明显低于对照组［（8.7±1.9）分比（10.9±1.7）分、（1.8±0.8）分比（3.9±1.5）分、（1.8±0.8）分比（6.2±1.4）分、（12.4±2.1）分比（20.4±1.3）分］(均P＜0.05)。观察组的总有效率明显高于对照组［93.8%（61/65）比67.7%（44/65）］（P＜0.01）。2组不良反应发生率差异无统计学意义（P＞0.05）。结论    西帕依麦孜彼子胶囊联合盐酸坦洛新缓释片治疗ⅢA型慢性非细菌性前列腺炎的临床效果确切，耐受性良好。

• Objective    To observe the clinical effect of Xipayimaibizi capsules combined with tamsulosin hydrochloride sustained-release tablets on type ⅢA chronic nonbacterial prostatitis. Methods    Totally 130 patients with type ⅢA chronic nonbacterial prostatitis from September 2010 to September 2013 in Affiliated Hospital of Chengde Medical University were randomly divided into observation group and control group, with 65 eases in each group. The observation group took Xipayimaibizi capsules(0.5 g/time, 3 times/d) and tamsulosin hydrochloride sustained-release tablets（0.2 mg/time, 2 times/d）. The control group took tamsulosin hydrochloride sustained-release tablets（0.2 mg/time, 2 times/d）. Both groups were treated for 5 weeks. Clinical efficacy was evaluated by the National Institutes of Health-Chronic Prostatitis Symptom Index（NIH-CPSI）. Adverse reactions were observed during treatment. Results    Scores of pain/discomfort, urination symptom, life quality and the total NIH-CPSI score after treatment in observation group were significantly lower than those in control group［（8.7±1.9） vs （10.9±1.7）, （1.8±0.8） vs （3.9±1.5）, （1.8±0.8） vs （6.2±1.4）, （12.4±2.1） vs （20.4±1.3）］(P＜0.05). Total effective rate in observation group was significantly higher than that in control group［93.8%（61/65） vs 67.7%（44/65）］（P＜0.01）. There was no significant difference of adverse reaction rate between groups（P＞0.05）. Conclusion    Xipayimaibizi capsules combined with tamsulosin hydrochloride sustained-release tablets are safe and effective in treatment of type ⅢA chronic nonbacterial prostatitis.